Nektar Therapeutics is a biopharmaceutical company that develops medicines for unmet medical needs. Its products include Bempegaldesleukin, NKTR-358, NKTR-255, and NKTR-262, which are in various stages of clinical trials for the treatment of cancer, autoimmune diseases, and COVID-19. The company has collaboration agreements with several pharmaceutical companies. Nektar Therapeutics was founded in 1990 and is based in San Francisco, California.